Clinical Trials Logo

Osteoporosis clinical trials

View clinical trials related to Osteoporosis.

Filter by:

NCT ID: NCT00536653 Completed - Osteoporosis Clinical Trials

Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

Start date: October 1999
Phase: N/A
Study type: Interventional

The aim of this study is to determine the long term effects of two types of hormonal treatment for advanced prostate cancer (LHRH agonists and the antiandrogen bicalutamide)on the bone mineral density of patients.

NCT ID: NCT00535860 Completed - Osteoporosis Clinical Trials

Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis

Start date: April 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the clinical efficacy, safety, and tolerability of ViaDerm-shPTH [1-34] transdermal delivery in comparison to subcutaneous injection of rhPTH[1-34] following 3-month treatment in postmenopausal women with Osteoporosis

NCT ID: NCT00533650 Completed - Clinical trials for Post-Menopausal Osteoporosis

Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)

Start date: December 2000
Phase: Phase 2
Study type: Interventional

A study to asses the safety and efficacy of MK0429 in postmenopausal women with osteoporosis.

NCT ID: NCT00532545 Completed - Clinical trials for Osteoporosis, Post-Menopausal

Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis

Start date: April 2003
Phase: Phase 4
Study type: Interventional

To test the hypothesis that Teriparatide injections given 20 micrograms/daily subcutaneously, for one month, are able to produce reliable changes in the bone marker in a severe osteoporotic population

NCT ID: NCT00532428 Completed - Clinical trials for Osteoporosis, Post-Menopausal

Long Term Effects of Raloxifene Treatment on Bone Quality

Start date: April 2003
Phase: Phase 4
Study type: Interventional

This is a cross-sectional study to determine, via iliac crest bone biopsies, the effect of long-term treatment with raloxifene on histomorphometry and bone quality in patients who participated in the Continuing Outcomes Relevant to Evista Study.

NCT ID: NCT00532337 Completed - Osteoporosis Clinical Trials

Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ONO-5334 in postmenopausal women with osteopenia or osteoporosis.

NCT ID: NCT00532207 Completed - Clinical trials for Osteoporosis, Post-Menopausal

Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

Start date: November 2003
Phase: Phase 3
Study type: Interventional

To see if using teriparatide for 12 months will increase Bone Mineral Density at the lumbar spine in postmenopausal women with osteoporosis

NCT ID: NCT00532077 Completed - Osteoporosis Clinical Trials

A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women

Start date: August 2007
Phase: Phase 1
Study type: Interventional

SB-751689 may alter calcium and phosphate handling at the kidney level. This study will examine what happens to calcium and phosphate, and other electrolytes, at the kidney after treatment with SB-751689 for 1 month. Another group of subjects will get another drug called Forteo for 1 month to compare the response of the kidney for calcium and phosphate.

NCT ID: NCT00529373 Terminated - Clinical trials for Postmenopausal Osteoporosis

A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

Start date: September 13, 2007
Phase: Phase 3
Study type: Interventional

The purpose of the event-driven base study is to determine the safety and efficacy, especially fracture risk reduction, of odanacatib in postmenopausal women diagnosed with osteoporosis. In a placebo-controlled extension of the base study, participants continued to receive the same blinded study medication for a total of up to 5 years of blinded study medication combined between the base study and the extension. After participants received 5 years of blinded study medication, they received open-label odanacatib through the end of the first extension. Participants were then invited to enroll in a second extension study in which they received open-label odanacatib for an additional 5 years. Two imaging substudies (PN032-Base/Extension and PN035) were conducted for participants in the MK-0822-018 Study. Additional safety information was collected for participants who discontinued from the base study or the blinded first extension in an observational follow-up study, MK-0822-083 (EudraCT number: 2007-002693-66) .

NCT ID: NCT00525798 Completed - Osteoporosis Clinical Trials

A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D

Start date: March 2007
Phase: Phase 3
Study type: Interventional

The purpose of this Phase III study is to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of patients with osteoporosis